{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:23:17Z","timestamp":1794313397785,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"AstraZeneca, Saudi Arabia","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eosinophilia is a significant factor in asthma severity; however, the prevalence of severe eosinophilic asthma in Saudi Arabia is largely unknown. We aimed to determine the prevalence of the eosinophilic (defined in this study as \u2265\u00a0300 cells\/mm<jats:sup>3<\/jats:sup> in blood), atopic (atopic phenotype 1, defined in this study as &gt;\u00a0100 IU\/mL total serum IgE; atopic phenotype 2, defined in this study as &gt;\u00a0150 IU\/mL), and overlap phenotypes among patients with severe asthma in Saudi Arabia.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional study was conducted in centers specialized in severe asthma management. Patients aged \u2265\u00a012 years with severe asthma were enrolled. Study patients responded to the Global Initiative for Asthma 2018 assessment of asthma control questionnaire and provided study investigators with current information related to the study objectives. Additional medical record data and a blood sample for total serum IgE and complete blood count were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 101 patients were enrolled; 83% were female and the mean (standard deviation) age was 48.7 (13.2) years. Forty-five (45%) patients had the eosinophilic phenotype, 50 (50%) had atopic phenotype 1, and 25 (25%) had phenotypic overlap (eosinophilic and atopic 1). Forty-one (41%) patients had atopic phenotype 2 and 23 (23%) had phenotypic overlap (eosinophilic and atopic 2). Asthma control and oral corticosteroid use patterns were similar and there were no significant differences in number of asthma exacerbations across phenotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In Saudi Arabia, 45% of patients with severe asthma had the eosinophilic phenotype, which is most likely an underestimation as no clinical features of eosinophilia were taken into account in the definition of eosinophilia. Approximately half of them had phenotypic overlap with the atopic phenotype.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>\u00a0NCT03931954; ClinicalTrials.gov, April 30, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-01856-9","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:03:05Z","timestamp":1645113785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Hamdan","family":"Al-Jahdali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr S.","family":"Albanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyad","family":"Allehebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al-Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Fattouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"1856_CR1","unstructured":"Global Asthma Network [homepage on the Internet]. The global asthma report.\u00a02018.\u00a0\u00a0http:\/\/www.globalasthmareport.org\/Global%20Asthma%20Report%202018.pdf. Accessed 12 Sept\u00a02020."},{"key":"1856_CR2","doi-asserted-by":"publisher","first-page":"8102527","DOI":"10.1155\/2018\/8102527","volume":"2018","author":"S Mohamed Hussain","year":"2018","unstructured":"Mohamed Hussain S, Ayesha Farhana S, Mohammed Alnasser S. Time trends and regional variation in prevalence of asthma and associated factors in Saudi Arabia: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:8102527.","journal-title":"Biomed Res Int"},{"key":"1856_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1056\/NEJMra1608969","volume":"377","author":"E Israel","year":"2017","unstructured":"Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377:965\u201376.","journal-title":"N Engl J Med"},{"key":"1856_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"1856_CR5","first-page":"848","volume":"22","author":"B Chastek","year":"2016","unstructured":"Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22:848\u201361.","journal-title":"J Manag Care Spec Pharm"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","volume":"3","author":"C Nunes","year":"2017","unstructured":"Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.","journal-title":"Asthma Res Pract"},{"key":"1856_CR7","doi-asserted-by":"publisher","first-page":"1700634","DOI":"10.1183\/13993003.00634-2017","volume":"49","author":"R Buhl","year":"2017","unstructured":"Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49:1700634.","journal-title":"Eur Respir J"},{"key":"1856_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/02770903.2019.1658205","volume":"58","author":"S Bhargava","year":"2021","unstructured":"Bhargava S, Holla AD, Jayaraj BS, Praveena AS, Ravi S, Khurana S, et al. Distinct asthma phenotypes with low maximal attainment of lung function on cluster analysis. J Asthma. 2021;58:26\u201337.","journal-title":"J Asthma"},{"key":"1856_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/02770903.2020.1786111","volume":"58","author":"MM Refaat","year":"2021","unstructured":"Refaat MM, El Sayed E, El-Fattah WA, Elbanna AH, El Sayed HM. Relationship between sputum periostin level and inflammatory asthma phenotypes in Egyptian patients. J Asthma. 2021;58:1285\u201391.","journal-title":"J Asthma"},{"key":"1856_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejim.2018.02.034","volume":"53","author":"FJ Gonzalez-Barcala","year":"2018","unstructured":"Gonzalez-Barcala FJ, San-Jose ME, Nieto-Fontarigo JJ, Carreira JM, Calvo-Alvarez U, Cruz MJ, et al. Association between blood eosinophil count with asthma hospital readmissions. Eur J Intern Med. 2018;53:34\u20139.","journal-title":"Eur J Intern Med"},{"key":"1856_CR11","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1183\/09031936.00118014","volume":"44","author":"FN Schleich","year":"2014","unstructured":"Schleich FN, Louis R. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44:1098\u20139.","journal-title":"Eur Respir J"},{"key":"1856_CR12","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","volume":"360","author":"RH Green","year":"2002","unstructured":"Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet. 2002;360:1715\u201321.","journal-title":"Lancet"},{"key":"1856_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.arbr.2019.03.023","volume":"56","author":"CP Casan","year":"2020","unstructured":"Casan CP, Gonzalez CM. Biologics in the treatment of asthma. Arch Bronconeumol (Engl Ed). 2020;56:137\u20138.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"1856_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.arbr.2019.08.016","volume":"56","author":"E Arismendi","year":"2020","unstructured":"Arismendi E, Valles CP. Current role of biomarkers in severe uncontrolled asthma. Arch Bronconeumol (Engl Ed). 2020;56:347\u20138.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"1856_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13223-018-0241-1","volume":"14","author":"D Husereau","year":"2018","unstructured":"Husereau D, Goodfield J, Leigh R, Borrelli R, Cloutier M, Gendron A, Severe. eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy Asthma Clin Immunol. 2018;14:15.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1856_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Resp Med. 2015;3:849\u201358.","journal-title":"Lancet Resp Med"},{"key":"1856_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/pai.13403","volume":"32","author":"N Mallah","year":"2021","unstructured":"Mallah N, Rodriguez-Segade S, Gonzalez-Barcala FJ, Takkouche B. Blood eosinophil count as predictor of asthma exacerbation. A meta-analysis. Pediatr Allergy Immunol. 2021;32:465\u201378.","journal-title":"Pediatr Allergy Immunol"},{"key":"1856_CR18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald MJ, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"1856_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799\u2013810.","journal-title":"Chest"},{"key":"1856_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Resp Med. 2014;2:879\u201390.","journal-title":"Lancet Resp Med"},{"key":"1856_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fphar.2013.00046","volume":"4","author":"SS Possa","year":"2013","unstructured":"Possa SS, Leick EA, Prado CM, Martins MA, Tib\u00e9rio IFLC. Eosinophilic inflammation in allergic asthma. Front Pharmacol. 2013;4:46.","journal-title":"Front Pharmacol"},{"key":"1856_CR22","first-page":"53","volume":"7","author":"HH Walford","year":"2014","unstructured":"Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014;7:53\u201365.","journal-title":"J Asthma Allergy"},{"key":"1856_CR23","doi-asserted-by":"publisher","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","volume":"1","author":"JC De Groot","year":"2015","unstructured":"De Groot JC, ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:00024\u20132015.","journal-title":"ERJ Open Res"},{"key":"1856_CR24","unstructured":"Global Initiative for Asthma (GINA) [homepage on the Internet]. Global strategy for asthma management and prevention (Updated 2018). https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/01\/2018-GINA.pdf. Accessed 13 Sept\u00a02020."},{"key":"1856_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","volume":"113","author":"C Miranda","year":"2004","unstructured":"Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101\u2013108.","journal-title":"J Allergy Clin Immunol"},{"key":"1856_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59\u201399.","journal-title":"Am J Respir Crit Care Med"},{"key":"1856_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","volume":"2","author":"RS Zeiger","year":"2014","unstructured":"Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Gossage D, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014;2:741\u201350.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1856_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","volume":"116","author":"TN Tran","year":"2016","unstructured":"Tran TN, Zeiger RS, Peters SP, Colice G, Newbold P, Goldman M, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116:37\u201342.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1856_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","volume":"108","author":"F Schleich","year":"2014","unstructured":"Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108:1723\u201332.","journal-title":"Respir Med"},{"key":"1856_CR30","doi-asserted-by":"publisher","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","volume":"1","author":"JC de Groot","year":"2015","unstructured":"de Groot JC, ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:00024.","journal-title":"ERJ Open Res"},{"key":"1856_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/resp.13841","volume":"26","author":"SA Hiles","year":"2021","unstructured":"Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: comparing severe asthma, COPD and asthma-COPD overlap. Respirology. 2021;26:52\u201361.","journal-title":"Respirology"},{"key":"1856_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/02770903.2018.1534967","volume":"56","author":"T Nagasaki","year":"2019","unstructured":"Nagasaki T, Sato K, Kume N, Oguma T, Sunadome H, Ito I, et al. The prevalence and disease burden of severe eosinophilic asthma in Japan. J Asthma. 2019;56:1147\u201358.","journal-title":"J Asthma"},{"key":"1856_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jaci.2009.06.029","volume":"124","author":"IH van Veen","year":"2009","unstructured":"van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol. 2009;124:615\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1856_CR34","doi-asserted-by":"crossref","unstructured":"Jackson D, Busby J, Heaney LG, Menzies-Gow A, Pfeffer P, Perez-de-Llano L, et al. A global survey of blood eosinophil distribution in severe asthma patients: data from the International Severe Asthma Registry (ISAR). InC21. Advances in adult and pediatric asthma phenotyping and endotyping.\u00a0 American Thoracic Society; 2020.\u00a0p. A4522-A4522","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4522"},{"key":"1856_CR35","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jaip.2013.07.009","volume":"1","author":"M Schatz","year":"2013","unstructured":"Schatz M, Zeiger RS, Zhang F, Chen W, Yang SJ, Camargo CA. Jr. Overweight\/obesity and risk of seasonal asthma exacerbations. J Allergy Clin Immunol Pract. 2013;1:618\u201322.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1856_CR36","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaci.2018.02.004","volume":"141","author":"U Peters","year":"2018","unstructured":"Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141:1169\u201379.","journal-title":"J Allergy Clin Immunol"},{"key":"1856_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.arbr.2020.10.010","volume":"57","author":"V Plaza","year":"2021","unstructured":"Plaza V, Blanco M, Garcia G, Korta J, Molina J, Quirce S, et al. Highlights of the Spanish Asthma Guidelines (GEMA), version 5.0. Arch Bronconeumol (Engl Ed). 2021;57:11\u20132.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"1856_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/JAA.S258594","volume":"13","author":"F Menzella","year":"2020","unstructured":"Menzella F, Ruggiero P, Ghidoni G, Fontana M, Bagnasco D, Livrieri F, et al. Anti-IL5 therapies for severe eosinophilic asthma: literature review and practical insights. J Asthma Allergy. 2020;13:301\u201313.","journal-title":"J Asthma Allergy"},{"key":"1856_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/02770903.2020.1748049","volume":"58","author":"ML Marques","year":"2021","unstructured":"Marques ML, Viana KP, Dos Santos FM, Saturnino LTM, Kormann ML, Lazaridis E, et al. Severe asthma and eligibility for biologics in a Brazilian cohort. J Asthma. 2021;58:958\u201366.","journal-title":"J Asthma"},{"key":"1856_CR40","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/02770903.2020.1753208","volume":"58","author":"S Varsano","year":"2021","unstructured":"Varsano S, Israeli L, Shitrit D. \"Severe-controlled\u201d asthma 4 years later: is it still controlled? J Asthma. 2021;58:1102\u201310.","journal-title":"J Asthma"},{"key":"1856_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41533-020-00194-9","volume":"30","author":"A Kaplan","year":"2020","unstructured":"Kaplan A, Szefler SJ, Halpin DMG. Impact of comorbid conditions on asthmatic adults and children. NPJ Prim Care Respir Med. 2020;30:36.","journal-title":"NPJ Prim Care Respir Med"},{"key":"1856_CR42","doi-asserted-by":"publisher","first-page":"e13655","DOI":"10.1111\/pai.13655","volume":"33","author":"N Mallah","year":"2022","unstructured":"Mallah N, Turner JM, Gonzalez-Barcala FJ, Takkouche B. Gastroesophageal reflux disease and asthma exacerbation: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2022;33:e13655.","journal-title":"Pediatr Allergy Immunol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01856-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T16:03:12Z","timestamp":1645113792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01856-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01856-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by each site\u2019s institutional review board (IRB), and all patients or their guardian provided written informed consent.  The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, the International Conference on Harmonization guidelines for Good Clinical Practice, the Good Participatory Practice Guidelines, and applicable laws and regulations in each participating country regarding non-interventional studies and\/or observational studies. The study was registered at  (NCT03931954), April 30, 2019. Ethical approvals were granted from: King Abdullah International Medical Research Center, King Abdulaziz University, and King Fahad Medical City.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mohmed Fattouh is an employee of AstraZeneca GCC and Maarten Beekman is an employee of AstraZeneca International. Hamdan Al-Jahdali, Siraj Wali,\n Amr S Albanna, Riyad Allehebi, and Hussein Al-Matar have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}